143 related articles for article (PubMed ID: 20925049)
21. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
[TBL] [Abstract][Full Text] [Related]
22. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
Waters LJ; Mandalia S; Gazzard B; Nelson M
AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
Cargnin S; Jommi C; Canonico PL; Genazzani AA; Terrazzino S
Pharmacogenomics; 2014 May; 15(7):963-76. PubMed ID: 24956250
[TBL] [Abstract][Full Text] [Related]
24. Current trends in screening across ethnicities for hypersensitivity to abacavir.
Rodriguez-Nóvoa S; Soriano V
Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539
[TBL] [Abstract][Full Text] [Related]
25. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.
Rodríguez-Nóvoa S; García-Gascó P; Blanco F; González-Pardo G; Castellares C; Moreno V; Jiménez-Nácher I; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1374-6. PubMed ID: 18184080
[TBL] [Abstract][Full Text] [Related]
26. HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay.
Hammond E; Mamotte C; Nolan D; Mallal S
Tissue Antigens; 2007 Jul; 70(1):58-61. PubMed ID: 17559582
[TBL] [Abstract][Full Text] [Related]
27. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
[TBL] [Abstract][Full Text] [Related]
28. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore?
Kapoor R; Martinez-Vega R; Dong D; Tan SY; Leo YS; Lee CC; Sung C; Ng OT; Archuleta S; Teo YY
Pharmacogenet Genomics; 2015 Feb; 25(2):60-72. PubMed ID: 25461248
[TBL] [Abstract][Full Text] [Related]
29. A new approach to safely type for HLA the HIV infected people eligible to abacavir therapy: saliva or buccal swab as reliable DNA sources.
Badulli C; Sbarsi I; Di Giorgio D; Mantovani M; Maserati R; Barbarini G; Salvaneschi L; Martinetti M
Clin Chim Acta; 2011 Oct; 412(21-22):1995-8. PubMed ID: 21767530
[TBL] [Abstract][Full Text] [Related]
30. HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing.
Martin AM; Nolan D; Mallal S
Tissue Antigens; 2005 Jun; 65(6):571-4. PubMed ID: 15896207
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.
Moragas M; Belloso WH; Baquedano MS; Gutierrez MI; Bissio E; Larriba JM; Fay F; Aulicino P; Gurevich JM; Yaunguzian MF; Maldonado AC; Falistocco C; Sen L; Mangano A
Tissue Antigens; 2015 Jul; 86(1):28-31. PubMed ID: 25922880
[TBL] [Abstract][Full Text] [Related]
32. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
Saag M; Balu R; Phillips E; Brachman P; Martorell C; Burman W; Stancil B; Mosteller M; Brothers C; Wannamaker P; Hughes A; Sutherland-Phillips D; Mallal S; Shaefer M;
Clin Infect Dis; 2008 Apr; 46(7):1111-8. PubMed ID: 18444831
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.
Hughes AR; Spreen WR; Mosteller M; Warren LL; Lai EH; Brothers CH; Cox C; Nelsen AJ; Hughes S; Thorborn DE; Stancil B; Hetherington SV; Burns DK; Roses AD
Pharmacogenomics J; 2008 Dec; 8(6):365-74. PubMed ID: 18332899
[TBL] [Abstract][Full Text] [Related]
34. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
Phillips EJ
Clin Infect Dis; 2006 Jul; 43(1):103-5. PubMed ID: 16758425
[No Abstract] [Full Text] [Related]
35. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.
Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C
J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774
[No Abstract] [Full Text] [Related]
36. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure.
Stainsby CM; Perger TM; Vannappagari V; Mounzer KC; Hsu RK; Henegar CE; Oyee J; Urbaityte R; Lane CE; Carter LM; Pakes GE; Shaefer MS
Pharmacotherapy; 2019 Jan; 39(1):40-54. PubMed ID: 30414209
[TBL] [Abstract][Full Text] [Related]
37. Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir.
Agbaji OO; Akanbi MO; Otoh I; Agaba PA; Akinsola R; Okolie V; Ugoagwu PO; Babadoko AA; Adediran A; Finomo FO; Abah JO; Muktar HM; Akanmu AS
Niger Postgrad Med J; 2019; 26(4):195-198. PubMed ID: 31621657
[TBL] [Abstract][Full Text] [Related]
38. External quality assessment of patient HLA-B*57:01 testing prior to abacavir prescription.
Darke C; Corbin SA
Int J Immunogenet; 2014 Aug; 41(4):277-80. PubMed ID: 24762294
[TBL] [Abstract][Full Text] [Related]
39. Successful translation of pharmacogenetics into the clinic: the abacavir example.
Phillips E; Mallal S
Mol Diagn Ther; 2009; 13(1):1-9. PubMed ID: 19351209
[TBL] [Abstract][Full Text] [Related]
40. Abacavir hypersensitivity.
Vandekerckhove L; Blot S; Vogelaers D
N Engl J Med; 2008 Jun; 358(23):2514-5; author reply 2515-6. PubMed ID: 18525052
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
